Drug monitoring and toxicology: A procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV

被引：40

作者：

Juenke, JM

Brown, PI

Urry, FM

McMillin, GA

机构：

[1] ARUP Labs Inc, ARUP Inst Clin & Expt Pathol, Salt Lake City, UT 84108 USA

[2] Univ Utah, Ctr Hlth Sci, Dept Pathol, Salt Lake City, UT 84132 USA

来源：

JOURNAL OF ANALYTICAL TOXICOLOGY | 2006年 / 30卷 / 01期

关键词：

D O I：

10.1093/jat/30.1.27

中图分类号：

O65 [分析化学];

学科分类号：

070302 ; 081704 ;

摘要：

This article describes a rapid isocratic high-performance liquid chromatographic (HPLC) method for the simultaneous measurement of the anticonvulsants levetiracetam and zonisamide. Monitoring these drugs is important for detecting potentially toxic concentrations, particularly in patients with renal impairment, but no commercial assays are currently available. Following a liquid-liquid extraction, levetiracetam (5-150 mu g/mL) and zonisamide (5-80 mu g/mL) are quantitated by HPLC-UV. The assay's limit of quantitation, linearity, imprecision, and accuracy adequately cover the therapeutic range of these drugs. The assay should be attractive to clinical laboratories because the run time for quantification of both drugs is approximately 5 min per sample, and no interferences are currently known.

引用

收藏

页码：27 / 30

页数：4

相关论文

共 34 条

[1] Levetiracetam monotherapy for newly diagnosed epilepsy patients [J].

Alsaadi, TM ;

Thieman, C .

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2003, 12 (03) :154-156

[2] Smoldering myeloma associated with zonisamide treatment [J].

Asai, S ;

Miyachi, H ;

Kobayashi, H ;

Hotta, T ;

Ando, Y .

INTERNAL MEDICINE, 2002, 41 (02) :138-141

[3] A case of levetiracetam (Keppra®) poisoning with clinical and toxicokinetic data [J].

Barrueto, F ;

Williams, K ;

Howland, MA ;

Hoffman, RS ;

Nelson, LS .

JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 2002, 40 (07) :881-884

[4] Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy [J].

Ben-Menachem, E ;

Edrich, P ;

Van Vleymen, B ;

Sander, JWA ;

Schmidt, B .

EPILEPSY RESEARCH, 2003, 53 (1-2) :57-64

[5] DETERMINATION OF ZONISAMIDE (3-SULPHAMOYLMETHYL-1,2-BENZISOXAZOLE) IN PLASMA AT THERAPEUTIC CONCENTRATIONS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].

BERRY, DJ .

JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 534 :173-181

[6] A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus [J].

Frucht, SJ ;

Louis, ED ;

Chuang, C ;

Fahn, S .

NEUROLOGY, 2001, 57 (06) :1112-1114

[7] Zonisamide for weight loss in obese adults - A randomized controlled trial [J].

Gadde, KM ;

Franciscy, DM ;

Wagner, HR ;

Krishnan, KRR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14) :1820-1825

[8] Correlation of levetiracetam concentrations between serum and saliva [J].

Grim, SA ;

Ryan, M ;

Miles, MV ;

Tang, PH ;

Strawsburg, RH ;

deGrauw, TJ ;

Fakhoury, TA ;

Baumann, RJ .

THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :61-66

[9] Enantioselective analysis of levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection [J].

Isoherranen, N ;

Roeder, M ;

Soback, S ;

Yagen, B ;

Schurig, V ;

Bialer, M .

JOURNAL OF CHROMATOGRAPHY B, 2000, 745 (02) :325-332

[10] Therapeutic drug monitoring of the newer antiepileptic drugs [J].

Johannessen, SI ;

Battino, D ;

Berry, DJ ;

Bialer, M ;

Krämer, G ;

Tomson, T ;

Patsalos, PN .

THERAPEUTIC DRUG MONITORING, 2003, 25 (03) :347-363

← 1 2 3 4 →